Hallam Conference Centre

44 Hallam Street, London W1W 6JJ

We are delighted to announce Dr David Steensma, Dana-Farber Cancer Institute who will lead an interactive session entitled Molecular diagnostics in the routine care of MDS patients, whey, when and how

Other topics will include:

  • Towards defining optimal transfusion practice in MDS
  • Alternatives to red cell transfusion in MDS
  • The management of thrombocytopenia in MDS, TPO agonists yes or no?
  • Case presentations and more


(click on the links to access the presentations)
Professor Jude Fitzgibbon: Slider




Online registration is now open - click here to register Registration Fee: £100.00

Please contact This email address is being protected from spambots. You need JavaScript enabled to view it. or telephone 07900 634948 for any further information.

Paper of the Month

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Visit our archives

IPSS-R MDS Risk Assessment Calculator

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator


Click here

MDS Fact Sheet

MDS Factsheet for GPs General Practicioners

MDS Fact Sheet

Click here

NICE Guideline

Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.

NICE logo

Click here

BSH Guidelines

This is an external link to the home of the British Society for Haematology (BSH). 

BSH Logo Strapline RGB

Click here